Improved glycaemic variability and time in range with dapagliflozin versus gliclazide modified release among adults with type 2 diabetes, evaluated by continuous glucose monitoring: A 12-week randomized controlled trial.
Andre G D ViannaClaudio S LacerdaLuciana M PechmannMichelle G PoleselEmerson C MarinoMauro ScharfJosiane M DetschKleber MarquesClaudia P SanchesPublished in: Diabetes, obesity & metabolism (2019)
Dapagliflozin improved GV and increased TIR more efficiently than gliclazide MR in individuals with type 2 diabetes over 12 weeks, as demonstrated by CGM.